[Skip to Content]
[Skip to Content Landing]

Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs Hospitals

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME
Key Points

Question  What are risk factors for severe breakthrough SARS-CoV-2 infections among vaccinated individuals?

Findings  In this cohort study of 110 760 vaccinated US veterans, increasing age was most strongly associated with severe disease, with risk increasing steadily among patients older than 50 years. Immunocompromising conditions and comorbidities indicating chronic heart, lung, kidney, or neurologic damage also increased risk, with a magnitude similar to or less than a 10-year age increase.

Meaning  Identification of the risk factors for severe breakthrough COVID-19 could be used to guide policies and decision-making about preventive measures for those who remain at risk of disease progression despite vaccination.

Abstract

Importance  With a large proportion of the US adult population vaccinated against SARS-CoV-2, it is important to identify who remains at risk of severe infection despite vaccination.

Objective  To characterize risk factors for severe COVID-19 disease in a vaccinated population.

Design, Setting, and Participants  This nationwide, retrospective cohort study included US veterans who received a SARS-CoV-2 vaccination series and later developed laboratory-confirmed SARS-CoV-2 infection and were treated at US Department of Veterans Affairs (VA) hospitals. Data were collected from December 15, 2020, through February 28, 2022.

Exposures  Demographic characteristics, comorbidities, immunocompromised status, and vaccination-related variables.

Main Outcomes and Measures  Development of severe vs nonsevere SARS-CoV-2 infection. Severe disease was defined as hospitalization within 14 days of a positive SARS-CoV-2 diagnostic test and either blood oxygen level of less than 94%, receipt of supplemental oxygen or dexamethasone, mechanical ventilation, or death within 28 days. Association between severe disease and exposures was estimated using logistic regression models.

Results  Among 110 760 patients with infections following vaccination (97 614 [88.1%] men, mean [SD] age at vaccination, 60.8 [15.3] years; 26 953 [24.3%] Black, 11 259 [10.2%] Hispanic, and 71 665 [64.7%] White), 10 612 (9.6%) had severe COVID-19. The strongest association with risk of severe disease after vaccination was age, which increased among patients aged 50 years or older with an adjusted odds ratio (aOR) of 1.42 (CI, 1.40-1.44) per 5-year increase in age, such that patients aged 80 years or older had an aOR of 16.58 (CI, 13.49-20.37) relative to patients aged 45 to 50 years. Immunocompromising conditions, including receipt of different classes of immunosuppressive medications (eg, leukocyte inhibitor: aOR, 2.80; 95% CI, 2.39-3.28) or cytotoxic chemotherapy (aOR, 2.71; CI, 2.27-3.24) prior to breakthrough infection, or leukemias or lymphomas (aOR, 1.87; CI, 1.61-2.17) and chronic conditions associated with end-organ disease, such as heart failure (aOR, 1.74; CI, 1.61-1.88), dementia (aOR, 2.01; CI, 1.83-2.20), and chronic kidney disease (aOR, 1.59; CI, 1.49-1.69), were also associated with increased risk. Receipt of an additional (ie, booster) dose of vaccine was associated with reduced odds of severe disease (aOR, 0.50; CI, 0.44-0.57).

Conclusions and Relevance  In this nationwide, retrospective cohort of predominantly male US Veterans, we identified risk factors associated with severe disease despite vaccination. Findings could be used to inform outreach efforts for booster vaccinations and to inform clinical decision-making about patients most likely to benefit from preexposure prophylaxis and antiviral therapy.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: September 19, 2022.

Published: October 20, 2022. doi:10.1001/jamanetworkopen.2022.40037

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Vo AD et al. JAMA Network Open.

Corresponding Author: Westyn Branch-Elliman, MD, MMSc, Department of Medicine, VA Boston Healthcare System, Section of Infectious Diseases, 1400 VFW Pkwy, West Roxbury, MA 02132 (Westyn.Branch-Elliman@va.gov).

Author Contributions: Drs Fillmore and Monach had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Mr Vo and Dr La equally contributed as first authors. Drs Branch-Elliman, Fillmore, and Monach equally contributed as senior authors.

Concept and design: Wu, Strymish, Ronan, Brophy, Do, Branch-Elliman, Fillmore, Monach.

Acquisition, analysis, or interpretation of data: Vo, La, Wu, Strymish, Branch-Elliman, Fillmore, Monach.

Drafting of the manuscript: Branch-Elliman, Fillmore, Monach.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Vo, La, Fillmore, Monach.

Obtained funding: Brophy.

Administrative, technical, or material support: Vo, Brophy, Do, Fillmore.

Supervision: Brophy, Do, Branch-Elliman, Fillmore, Monach.

Conflict of Interest Disclosures: Dr Branch-Elliman reported receiving grants from Gilead Sciences and funds to their institution during the conduct of the study. Dr Fillmore reported receiving grants from American Heart Association and grants from Veterans Affairs (VA) Cooperative Studies Program during the conduct of the study. No other disclosures were reported.

Funding/Support: This study was supported by the VA Cooperative Studies Program.

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: Views represented are those of the authors and do not necessarily represent those of the VA or the US Federal Government.

Additional Information: Patient-level data cannot be shared due to privacy laws. Code underlying the data will be made available upon request to the authors.

References
1.
Andrews  N , Stowe  J , Kirsebom  F ,  et al.  Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England.   Nat Med. 2022;28(4):831-837. doi:10.1038/s41591-022-01699-1PubMedGoogle ScholarCrossref
2.
Bar-On  YM , Goldberg  Y , Mandel  M ,  et al.  Protection of BNT162b2 vaccine booster against COVID-19 in Israel.   N Engl J Med. 2021;385(15):1393-1400. doi:10.1056/NEJMoa2114255PubMedGoogle ScholarCrossref
3.
Feikin  DR , Higdon  MM , Abu-Raddad  LJ ,  et al.  Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.   Lancet. 2022;399(10328):924-944. doi:10.1016/S0140-6736(22)00152-0PubMedGoogle ScholarCrossref
4.
VA Informatics and Computing Infrastructure. COVID-19 Shared Data Resource. US Department of Veterans Affairs; 2020.
5.
Fillmore  NR , La  J , Zheng  C ,  et al.  The COVID-19 hospitalization metric in the pre- and post-vaccination eras as a measure of pandemic severity: a retrospective, nationwide cohort study.   Infect Control Hosp Epidemiol. Published online January 11, 2022. doi:10.1017/ice.2022.13PubMedGoogle ScholarCrossref
6.
Corrigan  JK , La  J , Fillmore  NR ,  et al.  Coronavirus disease 2019 (COVID-19) hospitalization metrics that do not account for disease severity underestimate protection provided by severe acute respiratory coronavirus virus 2 (SARS-CoV-2) vaccination and boosting: a retrospective cohort study.   Infect Control Hosp Epidemiol. Published online May 23, 2022. doi:10.1017/ice.2022.79PubMedGoogle ScholarCrossref
7.
Centers for Medicare & Medicaid Services. Chronic Conditions Data Warehouse. Accessed November 30, 2021. https://www2.ccwdata.org/web/guest/condition-categories
8.
University of Toronto Department of Statistics. Odds ratios and relative risk. Accessed July 25, 2022. https://www.utstat.utoronto.ca/reid/odds.pdf
9.
Chen  H , Cohen  P , Chen  S .  How big is a big odds ratio? interpreting the magnitudes of odds ratios in epidemiological studies.   Commun Stat Simul Comput. 2010;39(4):860-864. doi:10.1080/03610911003650383Google ScholarCrossref
10.
Monach  P , Branch-Elliman  W . From pandemic to endemic. Contagion. 2022;7(1). Accessed September 20, 2022. https://www.contagionlive.com/view/from-pandemic-to-endemic
11.
Arbel  R , Wolff Sagy  Y , Hoshen  M ,  et al.  Nirmatrelvir use and severe COVID-19 outcomes during the Omicron surge.   N Engl J Med. 2022;387(9):790-798. doi:10.1056/NEJMoa2204919PubMedGoogle ScholarCrossref
12.
Yang  J , Zheng  Y , Gou  X ,  et al.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.   Int J Infect Dis. 2020;94:91-95. doi:10.1016/j.ijid.2020.03.017PubMedGoogle ScholarCrossref
13.
Garg  S , Kim  L , Whitaker  M ,  et al.  Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 States, March 1–30, 2020.   MMWR Morb Mortal Wkly Rep. 2020;69(15):458-464. doi:10.15585/mmwr.mm6915e3PubMedGoogle ScholarCrossref
14.
CDC COVID-19 Response Team.  Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020.   MMWR Morb Mortal Wkly Rep. 2020;69(13):382-386. doi:10.15585/mmwr.mm6913e2PubMedGoogle ScholarCrossref
15.
Fillmore  NR , Yellapragada  SV , Ifeorah  C ,  et al.  With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study.   Blood. 2019;133(24):2615-2618. doi:10.1182/blood.2019000406PubMedGoogle ScholarCrossref
16.
US Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). Accessed June 1, 2022. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covid-net/purpose-methods.html
17.
Dean  NE , Hogan  JW , Schnitzer  ME .  COVID-19 vaccine effectiveness and the test-negative design.   N Engl J Med. 2021;385(15):1431-1433. doi:10.1056/NEJMe2113151PubMedGoogle ScholarCrossref
18.
Yek  C , Warner  S , Wiltz  JL ,  et al.  Risk factors for severe COVID-19 outcomes among persons aged ≥18 years who completed a primary COVID-19 vaccination series—465 health care facilities, United States, December 2020-October 2021.   MMWR Morb Mortal Wkly Rep. 2022;71(1):19-25. doi:10.15585/mmwr.mm7101a4PubMedGoogle ScholarCrossref
19.
Galmiche  S , Luong Nguyen  LB , Tartour  E ,  et al.  Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.   Clin Microbiol Infect. 2022;28(2):163-177. doi:10.1016/j.cmi.2021.09.036PubMedGoogle ScholarCrossref
20.
Sun  J , Zheng  Q , Madhira  V ,  et al; National COVID Cohort Collaborative (N3C) Consortium.  Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US.   JAMA Intern Med. 2022;182(2):153-162. doi:10.1001/jamainternmed.2021.7024PubMedGoogle ScholarCrossref
21.
Goldberg  Y , Mandel  M , Bar-On  YM ,  et al.  Waning immunity after the BNT162b2 vaccine in Israel.   N Engl J Med. 2021;385(24):e85. doi:10.1056/NEJMoa2114228PubMedGoogle ScholarCrossref
22.
Andrews  N , Tessier  E , Stowe  J ,  et al.  Duration of protection against mild and severe disease by COVID-19 vaccines.   N Engl J Med. 2022;386(4):340-350. doi:10.1056/NEJMoa2115481PubMedGoogle ScholarCrossref
23.
Bhurwal  A , Mutneja  H , Bansal  V ,  et al.  Effectiveness and safety of SARS-CoV-2 vaccine in inflammatory bowel disease patients: a systematic review, meta-analysis and meta-regression.   Aliment Pharmacol Ther. 2022;55(10):1244-1264. doi:10.1111/apt.16913PubMedGoogle ScholarCrossref
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close